12:00 AM
 | 
Feb 21, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Azixa verubulin: Phase I data

A Phase I trial in 48 patients showed that once-weekly IV Azixa for 3 weeks of a 28-day cycle led to 5 cases of stable disease for >=4 months. The MTD was 3.3 mg/m...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >